Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2118-2125

  Pan, Kai Feng ^a   Formichella, Luca ^b   Zhang, Lian ^a   Zhang, Yang ^a   Ma, Jun Ling ^a   Li, Zhe Xuan ^a   Liu, Cong ^a   Wang, Yu Mei ^a   Goettner, Gereon ^c   Ulm, Kurt ^b   Classen, Meinhard ^b   You, Wei Cheng ^a   Gerhard, Markus ^b,d  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Mikrogen Diagnostics ^*  (Germany)

^d German Center for Infection Research   (Germany)

Author keywords

gastric cancer; Helicobacter pylori; precancerous gastric lesions; protein; serology

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CAGA PROTEIN; CHAPERONIN 60; GAMMA GLUTAMYLTRANSFERASE; HELICOBACTER CYSTEINE RICH PROTEIN C; HELICOBACTER PYLORI ANTIBODY; PROTEIN C; UNCLASSIFIED DRUG; UREASE; UREASE SUBUNIT A; VACUOLATING TOXIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; ATROPHIC GASTRITIS; CHINESE; CHRONIC ATROPHIC GASTRITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRECANCER; PRECANCEROUS GASTRIC LESION; PRIORITY JOURNAL; SEROPREVALENCE; STOMACH LESION;

GASTRIC CANCER; HELICOBACTER PYLORI; PRECANCEROUS GASTRIC LESIONS; PROTEIN; SEROLOGY;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ASIAN CONTINENTAL ANCESTRY GROUP; BACTERIAL PROTEINS; CHAPERONIN 60; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROEPIDEMIOLOGIC STUDIES; STOMACH NEOPLASMS;

EID: 84896722621     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28560     Document Type: Article

References (35)

1. Suerbaum S, Michetti P,. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
2. Correa P,. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-60.
3. Peek RM, Blaser M,. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37.
4. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-83.
5. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-92.
6. Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61: 812-18.
7. Polk DB, Peek RM,. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-14.
8. Correa P, Houghton J,. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-72.
9. Blaser MJ,. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila) 2008; 1: 308-11.
10. Wu W, Yang Y, Sun G,. Recent insights into antibiotic resistance in Helicobacter pylori eradication. Gastroenterol Res Pract 2012; 2012: 723183.
11. Hocker M, Hohenberger P,. Helicobacter pylori virulence factors-one part of a big picture. Lancet 2003; 362: 1231-3.
12. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-44.
13. Gao L, Michel A, Weck MN, et al. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res 2009; 69: 6164-70.
14. Gao L, Weck MN, Michel A, et al. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res 2009; 69: 2973-80.
15. Formichella L, Romberg L, Bolz C, et al. A novel immuno-line assay based on recombinant virulence factors enables highly specific and sensitive serological diagnosis of H. pylori infection. Clin Vaccine Immunol 2013; 20: 1703-1710.
16. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993; 53: 1317-21.
17. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
18. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24: 167-76.
19. 13C urea breath test. Am J Gastroenterol 1996; 91: 690-4.
20. You WC, Zhang L, Gail MH, et al. Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol 1998; 27: 941-4.
21. 13C-Urea Breath Test. Zhonghuaheyixuezaizhi 1994; 14: 103-5.
22. Zhang L, Blot WJ, You WC, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 1996; 5: 627-30.
23. Tu HK, Pan KF, Zhang Y, et al. Manganese superoxide dismutase polymorphism and risk of gastric lesions, and its effects on chemoprevention in a Chinese population. Cancer Epidemiol Biomarkers Prev 2010; 19: 1089-97.
24. Fock KM, Ang TL,. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010; 25: 479-86.
25. Vilaichone RK, Mahachai V, Tumwasorn S, et al. Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter 2004; 9: 453-9.
26. Groves FD, Perez-Perez G, Zhang L, et al. Serum antibodies to Helicobacter pylori and the CagA antigen do not explain differences in the prevalence of precancerous gastric lesions in two Chinese populations with contrasting gastric cancer rates. Cancer Epidemiol Biomarkers Prev 2002; 11: 1091-4.
27. You W-C, Zhang L, Pan K-F, et al. Helicobacter pylori prevalence and CagA status among children in two counties of china with high and low risks of gastric cancer. Ann Epidemiol 2001; 11: 543-6.
28. Dunn BE, Roop RM, II, Sung CC, et al. Identification and purification of a cpn60 heat shock protein homolog from Helicobacter pylori. Infect Immun 1992; 60: 1946-51.
29. Vanet A, Labigne A,. Evidence for specific secretion rather than autolysis in the release of some Helicobacter pylori proteins. Infect Immun 1998; 66: 1023-7.
30. Bergonzelli GE, Granato D, Pridmore RD, et al. GroEL of Lactobacillus johnsonii La1 (NCC 533) is cell surface associated: potential role in interactions with the host and the gastric pathogen Helicobacter pylori. Infect Immun 2006; 74: 425-34.
31. Macchia G, Massone A, Burroni D, et al. The Hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal diseases. Mol Microbiol 1993; 9: 645-52.
32. Kamoshida S, Satoh Y, Kamiya S, et al. Heat shock protein 60 (HSP60) immunoreactivity in gastric epithelium associated with Helicobacter pylori infection: a pitfall in immunohistochemically interpreting HSP60-mediated autoimmune responses. Pathol Int 1999; 49: 88-90.
33. Yamaguchi H, Osaki T, Kai M, et al. Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori. Infect Immun 2000; 68: 3448-54.
34. Schmees C, Prinz C, Treptau T, et al. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007; 132: 1820-33.
35. Gong M, Ling SSM, Lui SY, et al. Helicobacter pylori γ-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology 2010; 139: 564-73.